Sizing Up the Global Market for Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sizing Up the Global Market for Excipients
The global excipients market shows moderate growth, increased consolidation, and expansion activity in emerging markets and select product areas.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 62-68


Patricia Van Arnum
Excipients play an important role in pharmaceutical formulations by adding functionality or by facilitating the processing of a drug product. Despite this essential role in drug development and commercialization, as with other suppliers to the pharmaceutical industry, such as producers of raw materials, intermediates, or APIs, excipient manufacturers have to respond to the changing fundamentals influencing pharmaceutical supply and demand. In reviewing the recent activity of excipient manufacturers, several trends emerge: increased consolidation based on product-line enhancement or geographic expansion, select investment in emerging markets, and targeted growth in select product areas.

Crunching the numbers

The global excipients market is expected to grow at a moderate pace through 2016 in line with overall pharmaceutical industry growth. The global pharmaceutical market is expected to reach $1 trillion by 2014 and nearly $1.1 trillion by 2015, according to the IMS Institute for Healthcare Informatics. The market is projected to increase at a compound annual growth rate (CAGR) of 3–6% during the next five years, slowing from the 6.2% annual growth rate that occurred during the past five years. For purposes of this analysis, the pharmaceutical market includes all types of biopharmaceuticals, including biologics, over-the-counter drugs, and traditional medicines distributed and administered through regulated delivery systems, such as pharmacies, hospitals, clinics, physician offices, and mail order. Spending figures are reported as ex-manufacturer estimates that do not reflect off-invoice discounts and rebates (1).


IMAGE: NICHOLAS EVELEIGH / GETTY IMAGES
The global excipients market was valued at $4.6 billion in 2010 and is expected to reach $4.9 billion in 2011, according to a recent report by the market-research firm Business Communications Company (BCC). The global excipients market is expected to increase to $6.7 billion by 2016, representing a five-year CAGR of 6.5%. In terms of volume, 11.1 billion pounds of excipients are projected to be consumed in 2011. This level is expected to increase to 14 billion pounds by 2016, representing a CAGR in volume of 4.6%. BCC cites several factors influencing the global excipients market: concerns in the global pharmaceutical supply chain, application of quality by design in drug formulation and manufacturing, and overall concern for drug safety.

BCC segments the market for excipients into three major areas: organic excipients, inorganic excipients, and US Pharmacopeia (USP) water. Organic excipients represent the bulk of the global excipients market, accounting for approximately 93% by value in 2010. The market for organic excipients was valued at $4.3 billion 2010. It is expected to reach $4.5 billion in 2011 and $6.3 billion in 2016, representing a five-year CAGR of 6.6%. The market for inorganic excipients was $248 million in 2010. It is expected to reach $268 million in 2011 and $350 million by 2016, representing a five-year CAGR of 5.5%, according to BCC. USP water is the smallest segment in the global excipients market. In 2010, the market for USP water accounted for only $88 million. It is projected to increase to $92 million in 2011 and to $114 million by 2016, representing a five-year CAGR of 4.4%.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here